Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background/Aim: Liver biopsy has so far been the only method to accurately follow the progression of primary biliary cirrhosis (PBC). The stage and the severity of lymphocytic piecemeal necrosis (LPN) have been shown to be an independent factor for the development of cirrhosis. In this 3‐year prospective study, we evaluated the diagnostic value of several liver function tests, surrogate markers of fibrogenesis, hyaluronic acid (HA), procollagen III N‐terminal peptide (S‐PIIINP), cholestanol and plant sterols in noncirrhotic PBC patients treated with ursodeoxycholic acid (UDCA) or with UDCA and budesonide to assess the stage, inflammation and fibrosis. Methods: Seventy‐seven stage I–III PBC patients were included into the study, with control biopsy at 36 months. Serum liver enzymes, bile acids (BA), HA, PIIINP, immunoglobulins, lipids and cholesterol precursors and plant sterols were measured at baseline and at 36 months. Results: Aspartate aminotransferase (AST), HA, BA and PIINP were significantly different between stages I to III and differentiated mild (F0F1) from moderate (F2F3) fibrosis. The combination of these variables (PBC score) exhibited best sensitivity and specificity, compared with AST/platelet ratio, Forns' score and fibrosis index. Using a cut‐off value of 66 for the PBC score, the sensitivity was 81.4% and specificity was 65.2% for classifying the stage of PBC, regarding the stage the and fibrosis in noncirrhotic PBC. Conclusions: Serum HA, BA, PIIINP and AST may serve as valuable simple tools to monitor the treatment response to UDCA in early stages of PBC. Combinations of these biomarkers into a single index further potentiate the diagnostic value of such measurements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Corpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290301 · Cited by 234
Corpechot, C., Poujol‐Robert, A., Wendum, D., Galotte, M., Chrétien, Y., Poupon, R. E., & Poupon, R. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0918.x · Cited by 48
Cited by
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
“Several reports have tested the usefulness of serum biomarkers of liver fibrosis including serum levels of hyaluronic acid, procollagen III aminoterminal propeptide, collagen IV, and FibroTest! in patients with PBC [238–240].”
BackgroundCorpechot, C., Carrat, F., Poujol-Robert, A., Gaouar, F., Wendum, D., Chazouillères, O., & Poupon, R. (2012) · Hepatology · doi:10.1002/hep.25599 · Cited by 351
Umemura, T., Joshita, S., Sekiguchi, T., Usami, Y., Shibata, S., Kimura, T., Komatsu, M., Matsumoto, A., Ota, M., & Tanaka, E. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.118 · Cited by 127
“Although several fibrosis markers have been assessed for PBC,(24, 25) none have been established as surrogate markers in lieu of biopsy; only the European liver fibrosis test, which includes serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and N-terminal propeptide of type III procollagen, has shown acc…”
BackgroundInfluentialUtility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases
Corpechot, C. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.08.013 · Cited by 19
Metadata
- Authors
- Färkkilä, M., Rautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., & Niemelä, O.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2008-06-04
- Volume
- 28
- Issue
- 6
- Pages
- 787-797
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W1587549087
- Cited by
- 26
- References
- 6
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. https://app.cochat.ai/papers/10.1111/j.1478-3231.2008.01722.x
- The paper
- Färkkilä, M., Rautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., & Niemelä, O. (2008). Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver International. https://doi.org/10.1111/j.1478-3231.2008.01722.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.